Page 41 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 41

                                Dosimetry of immuno-PET with 89Zr-cmAb U36
REFERENCES
1. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol. 2008;26:1774-1777.
2. Börjesson PKE, Jauw YWS, Boellaard R, et al. Performance of immuno-positron emission tomography 2 with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node
metastases in head and neck cancer patients. Clin Cancer Res. 2006;12:2133-2140.
3. Verel I, Visser GWM, Dongen GA van. The Promise of Immuno-PET in Radioimmunotherapy. J Nucl Med. 2005;46:164S-171S.
4. Dongen GAMS van, Visser GWM, Hooge MNL, Vries EG de, Perk LR. Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications. The Oncologist. 2007;12:1379-1389.
5. Wu AM. Antibodies and Antimatter: The Resurgence of Immuno-PET. J Nucl Med. 2009;50:2-5.
6. Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides:
potentials and challenges. Bioconjug Chem. 2009;20:825-841.
7. Verel I, Visser GWM, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm. 2003;18:655- 661.
8. Perk LR, Visser GWM, Vosjan MJWD, et al. 89Zr as a PET Surrogate Radioisotope for Scouting Biodistribution of the Therapeutic Radiometals 90Y and 177Lu in Tumor-Bearing Nude Mice After Coupling to the Internalizing Antibody Cetuximab. J Nucl Med. 2005;46:1898-1906.
9. Perk LR, Visser OJ, Stigter-van Walsum M, et al. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:1337-1345.
10. Verel I, Visser GWM, Boellaard R, Walsum MS, Snow GB, Dongen GAMS van. 89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies. J Nucl Med. 2003;44:1271-1281.
11. Perk LR, Stigter-van Walsum M, Visser GWM, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35:1857-1867.
12. Brouwers A, Verel I, Van Eerd J, et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr- labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004;19:155-163.
13. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313-1319.
14. Aerts HJWL, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123-131.
15. Dijkers ECF, Kosterink JGW, Rademaker AP, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009;50:974-981.
16. Bree R de, Roos JC, Quak JJ, Hollander W den, Snow GB, Dongen GA van. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res. 1995;1:591-598.
17. Colnot DR, Quak JJ, Roos JC, et al. Phase I Therapy Study of 186Re-Labeled Chimeric Monoclonal Antibody U36 in Patients with Squamous Cell Carcinoma of the Head and Neck. J Nucl Med. 2000;41:1999-2010.
18. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GA. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targetting tumours in the upper aerodigestive and respiratory tract. Nucl Med Commun. 1994;15:613-627.
19. Heider KH, Mulder JW, Ostermann E, et al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer. 1995;31A:2385-2391.
20. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973- 978.
  39










































































   39   40   41   42   43